These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
269 related articles for article (PubMed ID: 26590655)
1. The disease-modifying effects of a Sativex-like combination of phytocannabinoids in mice with experimental autoimmune encephalomyelitis are preferentially due to Δ9-tetrahydrocannabinol acting through CB1 receptors. Moreno-Martet M; Feliú A; Espejo-Porras F; Mecha M; Carrillo-Salinas FJ; Fernández-Ruiz J; Guaza C; de Lago E Mult Scler Relat Disord; 2015 Nov; 4(6):505-11. PubMed ID: 26590655 [TBL] [Abstract][Full Text] [Related]
2. A Sativex(®) -like combination of phytocannabinoids as a disease-modifying therapy in a viral model of multiple sclerosis. Feliú A; Moreno-Martet M; Mecha M; Carrillo-Salinas FJ; de Lago E; Fernández-Ruiz J; Guaza C Br J Pharmacol; 2015 Jul; 172(14):3579-95. PubMed ID: 25857324 [TBL] [Abstract][Full Text] [Related]
3. Sativex-like combination of phytocannabinoids is neuroprotective in malonate-lesioned rats, an inflammatory model of Huntington's disease: role of CB1 and CB2 receptors. Valdeolivas S; Satta V; Pertwee RG; Fernández-Ruiz J; Sagredo O ACS Chem Neurosci; 2012 May; 3(5):400-6. PubMed ID: 22860209 [TBL] [Abstract][Full Text] [Related]
4. Combination of Cannabinoids, Δ9- Tetrahydrocannabinol and Cannabidiol, Ameliorates Experimental Multiple Sclerosis by Suppressing Neuroinflammation Through Regulation of miRNA-Mediated Signaling Pathways. Al-Ghezi ZZ; Miranda K; Nagarkatti M; Nagarkatti PS Front Immunol; 2019; 10():1921. PubMed ID: 31497013 [TBL] [Abstract][Full Text] [Related]
5. A Critical Review of the Role of the Cannabinoid Compounds Δ Jones É; Vlachou S Molecules; 2020 Oct; 25(21):. PubMed ID: 33113776 [TBL] [Abstract][Full Text] [Related]
7. Cannabinoids ameliorate disease progression in a model of multiple sclerosis in mice, acting preferentially through CB1 receptor-mediated anti-inflammatory effects. de Lago E; Moreno-Martet M; Cabranes A; Ramos JA; Fernández-Ruiz J Neuropharmacology; 2012 Jun; 62(7):2299-308. PubMed ID: 22342378 [TBL] [Abstract][Full Text] [Related]
8. Changes in endocannabinoid receptors and enzymes in the spinal cord of SOD1(G93A) transgenic mice and evaluation of a Sativex(®) -like combination of phytocannabinoids: interest for future therapies in amyotrophic lateral sclerosis. Moreno-Martet M; Espejo-Porras F; Fernández-Ruiz J; de Lago E CNS Neurosci Ther; 2014 Sep; 20(9):809-15. PubMed ID: 24703394 [TBL] [Abstract][Full Text] [Related]
9. The antinociceptive effect of Delta9-tetrahydrocannabinol in the arthritic rat involves the CB(2) cannabinoid receptor. Cox ML; Haller VL; Welch SP Eur J Pharmacol; 2007 Sep; 570(1-3):50-6. PubMed ID: 17588560 [TBL] [Abstract][Full Text] [Related]
10. Evaluation of prevalent phytocannabinoids in the acetic acid model of visceral nociception. Booker L; Naidu PS; Razdan RK; Mahadevan A; Lichtman AH Drug Alcohol Depend; 2009 Nov; 105(1-2):42-7. PubMed ID: 19679411 [TBL] [Abstract][Full Text] [Related]
11. Therapeutic potential of a novel cannabinoid agent CB52 in the mouse model of experimental autoimmune encephalomyelitis. Ribeiro R; Yu F; Wen J; Vana A; Zhang Y Neuroscience; 2013 Dec; 254():427-42. PubMed ID: 24036373 [TBL] [Abstract][Full Text] [Related]
12. Non-cannabinoid CB1, non-cannabinoid CB2 antinociceptive effects of several novel compounds in the PPQ stretch test in mice. Haller VL; Cichewicz DL; Welch SP Eur J Pharmacol; 2006 Sep; 546(1-3):60-8. PubMed ID: 16919265 [TBL] [Abstract][Full Text] [Related]
13. Effects of a Sativex-Like Combination of Phytocannabinoids on Disease Progression in R6/2 Mice, an Experimental Model of Huntington's Disease. Valdeolivas S; Sagredo O; Delgado M; Pozo MA; Fernández-Ruiz J Int J Mol Sci; 2017 Mar; 18(4):. PubMed ID: 28333097 [TBL] [Abstract][Full Text] [Related]
14. Combination of cannabinoids, delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD), mitigates experimental autoimmune encephalomyelitis (EAE) by altering the gut microbiome. Al-Ghezi ZZ; Busbee PB; Alghetaa H; Nagarkatti PS; Nagarkatti M Brain Behav Immun; 2019 Nov; 82():25-35. PubMed ID: 31356922 [TBL] [Abstract][Full Text] [Related]
15. Delta-9-tetrahydrocannabinol/cannabidiol (Sativex®): a review of its use in patients with moderate to severe spasticity due to multiple sclerosis. Syed YY; McKeage K; Scott LJ Drugs; 2014 Apr; 74(5):563-78. PubMed ID: 24671907 [TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of Sativex® in Dogs: Towards a Potential Cannabinoid-Based Therapy for Canine Disorders. Fernández-Trapero M; Pérez-Díaz C; Espejo-Porras F; de Lago E; Fernández-Ruiz J Biomolecules; 2020 Feb; 10(2):. PubMed ID: 32054131 [TBL] [Abstract][Full Text] [Related]
17. Cannabinoid receptor-mediated disruption of sensory gating and neural oscillations: A translational study in rats and humans. Skosnik PD; Hajós M; Cortes-Briones JA; Edwards CR; Pittman BP; Hoffmann WE; Sewell AR; D'Souza DC; Ranganathan M Neuropharmacology; 2018 Jun; 135():412-423. PubMed ID: 29604295 [TBL] [Abstract][Full Text] [Related]
18. Peripheral, but not central effects of cannabidiol derivatives: mediation by CB(1) and unidentified receptors. Fride E; Ponde D; Breuer A; Hanus L Neuropharmacology; 2005 Jun; 48(8):1117-29. PubMed ID: 15910887 [TBL] [Abstract][Full Text] [Related]
19. Effect of low doses of delta9-tetrahydrocannabinol and cannabidiol on the extinction of cocaine-induced and amphetamine-induced conditioned place preference learning in rats. Parker LA; Burton P; Sorge RE; Yakiwchuk C; Mechoulam R Psychopharmacology (Berl); 2004 Sep; 175(3):360-6. PubMed ID: 15138755 [TBL] [Abstract][Full Text] [Related]
20. The detection of THC, CBD and CBN in the oral fluid of Sativex® patients using two on-site screening tests and LC-MS/MS. Molnar A; Fu S; Lewis J; Allsop DJ; Copeland J Forensic Sci Int; 2014 May; 238():113-9. PubMed ID: 24699310 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]